z-logo
Premium
QT/QTc study conducted in Japanese adult healthy subjects: A novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation
Author(s) -
Sugiyama Atsushi,
Hashimoto Hiroya,
Nakamura Yuji,
Fujita Tomoe,
Kumagai Yuji
Publication year - 2014
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/jcph.226
Subject(s) - moxifloxacin , qt interval , medicine , placebo , anesthesia , xanthine oxidase inhibitor , crossover study , cardiology , pharmacology , xanthine oxidase , chemistry , biochemistry , alternative medicine , pathology , enzyme , antibiotics
A QT/QTc study was conducted in compliance with ICH E14 guideline to evaluate the effects of a new xanthine oxidase inhibitor topiroxostat in Japanese healthy subjects. Forty‐eight Japanese healthy subjects (males 24; females 24) received a single oral dose of topiroxostat (60 or 180 mg), moxifloxacin (400 mg) or placebo in a single‐center, double‐blind, four‐period crossover design. Fridericia's formula (QTcF = QT/RR 0.33 ) was used as a primary method for QT‐interval correction. The mean QTcF was prolonged by moxifloxacin, of which largest time‐matched difference from placebo administration was 13.6 milliseconds with 90% confidence interval (CI) of 11.2 and 15.9 milliseconds at 4 hours post‐dose. The mean QTcF was hardly affected by either dose of topiroxostat, of which largest time‐matched difference from placebo administration was 2.9 milliseconds with 90% CI of 0.6 and 5.3 milliseconds at 4 hours post‐dose for 60 mg, and 2.3 milliseconds with 90% CI of 0 and 4.7 milliseconds at 1 hour post‐dose for 180 mg. The results were essentially the same in the sex subgroup analysis. Moxifloxacin can be used as a positive control for QT/QTc studies in Japanese subjects; and topiroxostat may not cause QT‐interval prolongation in males as well as females.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here